News › Industry News, News

Breaking Business News: Allergan Acquires Bonti

September 18, 2018

Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications.
Following completion of the acquisition, Allergan will obtain global rights to Bonti’s pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development, EB-001A (aesthetic) and EB-001T (therapeutic).
Read more at DermWire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics
    • Glendale Doctor Convicted in $45 Million Botox Fraud Scheme
    • Moxie Announces Treatment Plans
    • Pacific Reliance Medical M&A Advisors Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Hydrafacial Introduces HydraScalp with Keravive